Table IV.
Effect of LEM vs. placebo on immunological parameters during the study course.
| First course | Second course | ||||||
|---|---|---|---|---|---|---|---|
| Parameters | Groups | Subject no. | Day 1 | Day 8 | Day 22 | Day 8 | Day 22 |
| NK cell activity (%) | LEM | 23 | 32.5±3.7 | 19.1±2.9b | 23.4±2.4b | 13.6±1.7b | 25.2±2.7a |
| Placebo | 19 | 27.4±3.1 | 16.2±1.9b | 20.4±1.8 | 10.8±2.2b | 23.2±2.9 | |
| Treg (Foxp3+ CD25+/CD4+ | LEM | 23 | 6.2±0.3 | 5.2±0.3a | 6.6±0.4 | 5.5±0.2 | 7.3±0.4b |
| cells) (%) | Placebo | 19 | 5.8±0.3 | 5.1±0.3 | 6.6±0.4a | 5.6±0.4 | 7.6±0.4b |
| Th1/Th2 balance (IFN-γ+/IL-4+ | LEM | 23 | 10.1±1.5 | 8.7±1.3 | 9.2±1.1 | 7.7±0.9 | 8.1±1.0 |
| in CD4+ cells) | Placebo | 19 | 10.3±1.4 | 9.5±1.2 | 10.1±1.1 | 8.7±1.1 | 10.5±1.3 |
Measurement values are shown as means ± standard error. Variation within each group was assayed by repeated one-way analysis of variance with Bonferroni's correction vs. day 1 of the first course.
a
P<0.05
b
P<0.01. LEM, Lentinula edodes mycelia extract; NK, natural killer; Treg, regulatory T cells; IFN, interferon; IL, interleukin.